Related Experiment Video
Updated: Feb 20, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Cumulative Exposure to High-Sensitivity C-Reactive Protein Predicts the Risk of Cardiovascular Disease
Aitian Wang1,2,3, Jie Liu4, Chunguang Li5
1Tianjin Medical University, Tianjin, China.
Insights
Cumulative exposure to high-sensitivity C-reactive protein (hs-CRP) is linked to higher cardiovascular disease (CVD) and heart attack risks. This study quantifies the dose-dependent relationship between prolonged hs-CRP elevation and these adverse cardiovascular events.
Area of Science:
- Biomedical research
- Cardiovascular epidemiology
- Inflammation markers
Background:
- Elevated high-sensitivity C-reactive protein (hs-CRP) is a known risk factor for cardiovascular disease (CVD).
- Understanding the impact of cumulative hs-CRP exposure over time is crucial for risk stratification.
Purpose of the Study:
- To investigate the association between cumulative exposure to elevated hs-CRP levels and the incidence of cardiovascular events.
- To determine if a dose-response relationship exists between the duration of hs-CRP elevation and CVD risk.
Main Methods:
- A cohort of 53,065 participants had hs-CRP measured at three time points (2006, 2008, 2010).
- Cumulative hs-CRP exposure was calculated using a weighted sum of hs-CRP levels over time.
- Participants were categorized into groups based on the number of examinations with hs-CRP ≥ 3.0 mg/L.
- Cox proportional hazards models were employed to analyze the association with incident CVD.
Main Results:
- A significant dose-response relationship was observed between cumulative hs-CRP exposure and the risk of CVD and myocardial infarction.
- Participants with hs-CRP ≥ 3.0 mg/L in all three examinations (3-exposed group) showed a 1.38-fold increased CVD risk.
- The 3-exposed group also had a 2.13-fold increased risk of myocardial infarction compared to the non-exposed group.
- No statistically significant association was found between cumulative hs-CRP and stroke risk.
Conclusions:
- Cumulative exposure to hs-CRP demonstrates a dose-dependent association with increased risks of cardiovascular disease and myocardial infarction.
- The findings underscore the importance of sustained hs-CRP elevation as a predictor of major adverse cardiovascular events.
Background:
One measurement of hs-CRP (high-sensitivity C-reactive protein) is associated with increased risk of cardiovascular disease (CVD). The objective of this study was to characterize the association of cumulative exposure to increased hs-CRP with incident cardiovascular events.
Methods And Results:
We included 53 065 participants with hs-CRP measured at 3 examinations in 2006, 2008, and 2010. Cumulative exposure to hs-CRP was calculated as the weighted sum of the average hs-CRP level for each time interval (level×time). Participants were classified into nonexposed group (hs-CRP<3.0 mg/L in all 3 examinations), 1-exposed group (hs-CRP≥3.0 mg/L in 1 of the 3 examinations), 2-exposed group (hs-CRP≥3.0 mg/L in 2 of the 3 examinations), and 3-exposed group (hs-CRP≥3.0 mg/L in 3 examinations). Cox proportional hazards models were used to assess the association of cumulative hs-CRP with incident CVD. The study showed a dose-response pattern with risk of CVD and myocardial infarction as the number of years of exposure to hs-CRP increases. Participants in the 3-exposed group had significantly increased CVD risk with hazard ratio (95% confidence interval) of 1.38 (1.11-1.72), in comparison with 1.28 (1.07-1.52) for participants in the 2-exposed group and 1.13 (0.97-1.31) for those in the 1-exposed group (P<0.05); meanwhile, the similar and significant associations were also observed for myocardial infarction with respective hazard ratio (95% confidence interval) of 2.13 (1.42-3.18), 1.60 (1.12-2.27), and 1.57 (1.17-2.10). The associations between stroke and cumulative hs-CRP were not statistically significant (P=0.360).
Conclusions:
Cumulative exposure to hs-CRP was dose dependently associated with a subsequent increased risk of CVD and myocardial infarction.
Clinical Trial Registration:
URL: https://www.clinicaltrials.gov/. Unique identifier: ChiCTR-TNC-11001489.
More Related Videos
08:51Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:27Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
01:30Coronary Artery Disease I: Introduction
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:23Rheumatic Heart Disease I: Introduction
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies